Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Systemic sclerosis
If a patient with limited scleroderma presents with the three active domains including skin thickening, inflammatory joint pain, and ILD would you consider starting Actemra?
Related Questions
Are there situations in which you treat calcinosis cutis that is not symptomatic for the patient?
How do you approach the significance of +RNP III antibody in a patient with positive ANA but no other signs or symptoms of systemic sclerosis?
What is the clinical significance of an isolated anti-centromere B antibody in a patient with pulmonary fibrosis but no other features of systemic sclerosis?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
How do you approach initial steroid dosing in patients with eosinophilic fasciitis?
What treatment regimen would you recommend for a patient with biopsy-proven giant cell arteritis and diffuse cutaneous systemic sclerosis?
What are some important considerations for use of ACE inhibition in scleroderma renal crisis patients who require dialysis?
Would you continue belimumab in high risk lupus patients with overlapping scleroderma features with ILD who become pregnant and who are already on HCQ and azathioprine?
How would you approach a patient with anti-scl70 ab positive sine scleroderma complicated by ILD who also has seropositive RA with active arthritis?
How do you envision incorporating CAR-T therapy into your clinical practice?
